BCL2 and breast carcinoma: Similar results were given when EG was tested against the human breast cancer cells (MDA-MB-231 (ER-) invasion and showed to modulate the PI3K/Akt pathway and to inhibit their downstream targets such as Bcl-2/Bax at mRNA levels [8].